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Screening	 of	 the	 syndromic	 genes	 is	 not	 routinely	 performed	
as	part	of	the	genetic	testing	strategy	for	individuals	with	HH.	The	
targeted	 analysis	 of	 a	 gene	 is	 usually	 only	 performed	when	 there	
is	 a	 clinical	 suspicion	 of	 a	 specific	 syndrome	 in	 an	 individual	 and	









performed	 a	 comprehensive	 analysis	 of	 genome	 sequencing	 data	




2  | MATERIAL S AND METHODS
2.1 | Patient details
82	infants	with	HH	diagnosed	within	the	first	12	months	of	life	were	
referred	 for	genetic	 testing	 to	 the	Molecular	Genetics	Laboratory	
at	the	Royal	Devon	and	Exeter	NHS	Foundation	Trust.	All	patients	
in	 the	cohort	had	 received	a	biochemical	diagnosis	of	HH	 in	 their	
local	centre.	All	patients	had	a	blood	glucose	of	<2.8	mmol/L	(me-
dian	1.9	mmol/L)	with	a	concomitant	insulin	of	>15	pmol/L	(median	
96	pmol/L)	 and/or	 a	 c‐peptide	of	>300	pmol/L	 (see	Table	1).	 In	 all	





the	time	of	study.	Mutations	in	the	ABCC8, KCNJ11, HADH, HNF4A, 
HNF1A, GLUD1, GCK, and SLC16A1	genes	had	been	excluded	in	all	
patients	 using	 targeted	 next‐generation	 sequencing.11 The cod-
ing	 regions	of	 the	HH	candidate	genes,	UCP2 and HK1,	were	also	
screened	 but	 no	 likely	 pathogenic	 variants	were	 identified	 in	 the	
cohort.12‐14 
The	 study	was	 approved	 by	 the	North	Wales	 Research	 Ethics	
Committee.	Consent	was	obtained	from	each	patient	after	 full	ex-
planation	of	the	purpose	and	nature	of	all	procedures	used.
2.2 | Gene panel and variant calling
We	utilized	the	Phenomizer	browser	to	identify	disease	entries	an-
notated	for	hyperinsulinaemic	hypoglycaemia	(HPO	id:	0000825).15 
A	survey	of	 the	 literature	was	also	undertaken	 to	 identify	 further	
genes	in	which	mutations	have	been	reported	to	cause	HH	as	part	
of	a	syndrome.
Whole‐genome	 sequencing	 was	 performed	 on	 DNA	 extracted	







realignment	 and	 running	 the	base	quality	 score	 realignment.	GATK	














Extra‐pancreatic	features n = 15
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TA B L E  2  Syndromes	in	which	hyperinsulinaemic	hypoglycaemia	(HH)	has	been	reported	as	a	feature.	The	18	genes	in	which	mutations	
have	been	reported	to	cause	syndromic	HH	plus	the	three	genomic	regions	known	to	be	affected	by	copy	number	variants	(CNVs)	or	
uniparental	isodisomy	(UPD)	are	provided.
Syndrome OMIM Gene(s) Inheritance References HH clinical featuresa
Adenosine	kinase	
deficiency




ALG3 Recessive Sun	et	al7 Neonatal	onset
Timothy CACNA1C Dominant Splawski	et	al24 Childhood	onset.	
Recurrent









Perlman DIS3L2 Recessive Henneveld	et	al26 Onset	from	birth
Tyrosinaemia	type	I FAH Recessive Baumann	et	al27 Neonatal	onset.	Transient.	
Diazoxide	responsive
Simpson‐Golabi‐Behmel GPC3 X‐linked	recessive Terespolsky	et	al28 Neonatal	onset





INSR Dominant Hojlund	et	al30 Onset	3	to	30	years	of	age.	
Postprandial	HH.	
Octreotide	responsive




























PMM2 Recessive Cabezas	et	al9 Neonatal/childhood	onset.	
Persistent.	Diazoxide	
responsive
TRMT10A TRMT10A Recessive Gillis	et	al34 Childhood	onset.	
Persistent.	Diazoxide	
responsive
Patau	syndrome Trisomy	13  De novo Smith	and	Giacoia35 Onset	from	birth.	
Transient
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haplotypeCaller	was	used	to	identify	variants,	which	were	annotated	




(details	 of	 primer	 sequences	 are	 available	 on	 request).	 CNVs	were	
called	by	SavvyCNV,	which	uses	 read	depth	 to	 judge	copy	number	
states.17	Uniparental	isodisomy	was	detected	using	a	hidden	Markov	
model	 to	 detect	 regions	with	 a	 significant	 number	 of	 variants	 that	
were	opposite	homozygous	between	the	proband	and	one	parent.
3  | RESULTS
We	 identified	 20	 genetic	 syndromes	 in	 which	 HH	 has	 been	 re-
ported	 as	 a	 feature	 (Table	2).	 In	 82	 patients,	 we	 screened	 the	
coding	regions	and	intron/exon	boundaries	of	the	18	genes	associ-
ated	with	these	syndromes.	We	also	searched	for	copy	number	var-
iations	 (CNVs)	 and	evidence	of	uniparental	 isodisomy	at	genomic	























a	 46XX	 karyotype,	 which	 excluded	 Patau	 and	 Turner	 syndromes,	
respectively.
The	 heterozygous	 frameshift	 variant	 in	 the	 KMT2D	 gene	
p.(Lys5244Serfs*13),	 (c.15731_15732del)	 and	 (NM_003482.3)	











at	30	days,	which	 resulted	 in	euglycaemia.	Hyperinsulinism	as	 the	
cause	of	hypoglycaemia	was	confirmed	biochemically.	The	patient	
required	continuous	diazoxide	treatment	and	a	nasogastric	tube	for	
feeding.	 At	 the	 age	 of	 6	months,	 the	 patient	was	 referred	 for	 ge-
netic	testing	of	the	genes	causing	isolated	HH.	At	referral,	the	only	
extra‐pancreatic	 feature	 reported	 to	 the	 genetics	 laboratory	 was	
gastro‐oesophageal	reflux.	At	follow‐up	subsequent	to	the	genetic	
diagnosis,	 clinical	 features	 consistent	 with	 a	 diagnosis	 of	 Kabuki	
syndrome	were	 reported.	At	 the	age	of	5	months,	her	weight	was	
6.06	kg	 (10th‐50th	 centile),	 height	was	 60	cm	 (<10th	 centile),	 and	
head	circumference	was	38.5	cm	(<10th	centile).	She	had	soft	facial	
dysmorphism,	 hypotonia	 and	 laryngomalacia	 with	 inspiratory	 stri-
dor.	Her	gross	and	 fine	motor	development	was	delayed.	She	also	





to	 feature	as	part	of	 a	 complex	 syndrome	 in	82	patients	with	HH	








cal	 geneticist,	 a	 clinical	diagnosis	of	Kabuki	 syndrome	would	have	
been	made.	As	 the	patient	died	before	 the	 age	of	1	year,	 it	 is	 not	









Mutations	 in	 the	 “syndromic”	 HH	 genes	 were	 not	 identified	
in	the	majority	of	our	cohort	 (81/82	patients).	Our	patients	were	
selected	due	to	the	presence	of	persistent	HH	rather	than	a	syn-
dromic	 phenotype.	Our	 low	pickup	 rate	 suggests	 that	mutations	
in	 these	 genes	 are	 rare	 in	 patients	 presenting	with	 isolated	HH.	
It	 is	 likely	 that	 for	 the	majority	of	 cases	with	 syndromic	disease,	
additional	 features	 are	 evident	 from	 birth	 allowing	 for	 a	 clinical	
diagnosis	 followed	 by	 confirmatory	 genetic	 testing.	 This	 would	
consequently	 reduce	 the	 prevalence	 of	 cases	 within	 our	 cohort	
as	 the	majority	 of	 patients	 are	 referred	 for	 routine	 screening	 of	
the	8	known	 isolated	HH	genes.	Heterozygous	variants	 in	genes	










The	 finding	 that	 the	patient	with	Kabuki	 syndrome	had	HH	as	
the	presenting	feature	highlights	the	potential	benefit	of	screening	









nosis	 of	 a	 syndrome	has	 benefits	 for	 patient	 care.	However,	 there	
are	some	disadvantages	of	this	approach	in	terms	of	the	difficulties	


















tations	 in	 the	syndromic	HH	genes	are	 rare	 in	 individuals	 referred	
for	 routine	 testing	 for	HH.	Given	 the	 time‐consuming	nature	of	 a	
comprehensive	screen,	routine	testing	of	these	genes	by	molecular	
genetics	 laboratories	 is	 unlikely	 to	be	 justified	 in	patients	without	
syndromic	phenotypes.
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